Go Pro
→ Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown” (From Paradigm Press) (Ad)tc pixel Free VINC Stock Alerts

Vincerx Pharma (VINC) Competitors

Vincerx Pharma logo
$0.01 0.00 (0.00%)
As of 08/13/2026 03:35 PM Eastern
Compare

VINC vs. AMPE, CARM, PTPI, CLVR, and SCPS

Should you buy Vincerx Pharma stock or one of its competitors? Vincerx Pharma's main competitors and comparable companies include Ampio Pharmaceuticals (AMPE), Carisma Therapeutics (CARM), Petros Pharmaceuticals (PTPI), Clever Leaves (CLVR), and Scopus BioPharma (SCPS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Vincerx Pharma compare to Ampio Pharmaceuticals?

Ampio Pharmaceuticals (NYSE:AMPE) and Vincerx Pharma (NASDAQ:VINC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

Ampio Pharmaceuticals has a beta of 5.96, meaning that its stock price is 496% more volatile than the broader market. Comparatively, Vincerx Pharma has a beta of 1.44, meaning that its stock price is 44% more volatile than the broader market.

Ampio Pharmaceuticals' return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Ampio PharmaceuticalsN/A N/A N/A
Vincerx Pharma N/A -248.33%-132.73%

5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are owned by institutional investors. 3.3% of Ampio Pharmaceuticals shares are owned by company insiders. Comparatively, 15.6% of Vincerx Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled Vincerx Pharma'saverage media sentiment score.

Company Overall Sentiment
Ampio Pharmaceuticals Neutral
Vincerx Pharma Neutral

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ampio PharmaceuticalsN/AN/A-$8.63M-$11.01N/A
Vincerx PharmaN/AN/A-$40.16M-$5.31N/A

Summary

Ampio Pharmaceuticals and Vincerx Pharma tied by winning 4 of the 8 factors compared between the two stocks.

How does Vincerx Pharma compare to Carisma Therapeutics?

Vincerx Pharma (NASDAQ:VINC) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Vincerx Pharma has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Vincerx PharmaN/A -248.33% -132.73%
Carisma Therapeutics -254.28%N/A -192.17%

Vincerx Pharma has higher earnings, but lower revenue than Carisma Therapeutics. Vincerx Pharma is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vincerx PharmaN/AN/A-$40.16M-$5.31N/A
Carisma Therapeutics$10.77M0.01-$60.48M$0.730.00

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vincerx Pharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Carisma Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Vincerx Pharma's average media sentiment score of 0.00 equaled Carisma Therapeutics'average media sentiment score.

Company Overall Sentiment
Vincerx Pharma Neutral
Carisma Therapeutics Neutral

Vincerx Pharma has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of -9.09, suggesting that its share price is 1,009% less volatile than the broader market.

44.0% of Vincerx Pharma shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 15.6% of Vincerx Pharma shares are owned by company insiders. Comparatively, 6.9% of Carisma Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Carisma Therapeutics beats Vincerx Pharma on 6 of the 11 factors compared between the two stocks.

How does Vincerx Pharma compare to Petros Pharmaceuticals?

Vincerx Pharma (NASDAQ:VINC) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

Vincerx Pharma has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market. Comparatively, Petros Pharmaceuticals has a beta of 1.88, suggesting that its share price is 88% more volatile than the broader market.

44.0% of Vincerx Pharma shares are held by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by institutional investors. 15.6% of Vincerx Pharma shares are held by insiders. Comparatively, 8.2% of Petros Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Petros Pharmaceuticals' return on equity of -78.22% beat Vincerx Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Vincerx PharmaN/A -248.33% -132.73%
Petros Pharmaceuticals N/A -78.22%-23.50%

Petros Pharmaceuticals has higher revenue and earnings than Vincerx Pharma. Vincerx Pharma is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vincerx PharmaN/AN/A-$40.16M-$5.31N/A
Petros Pharmaceuticals$5.11M0.02-$8.16M-$1.64N/A

In the previous week, Vincerx Pharma's average media sentiment score of 0.00 equaled Petros Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Vincerx Pharma Neutral
Petros Pharmaceuticals Neutral

Summary

Petros Pharmaceuticals beats Vincerx Pharma on 6 of the 9 factors compared between the two stocks.

How does Vincerx Pharma compare to Clever Leaves?

Clever Leaves (NASDAQ:CLVR) and Vincerx Pharma (NASDAQ:VINC) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

Clever Leaves has a beta of 3816.13, indicating that its share price is 381,513% more volatile than the broader market. Comparatively, Vincerx Pharma has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market.

Clever Leaves has higher revenue and earnings than Vincerx Pharma. Vincerx Pharma is trading at a lower price-to-earnings ratio than Clever Leaves, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clever Leaves$17.42M0.00-$17.90M-$12.36N/A
Vincerx PharmaN/AN/A-$40.16M-$5.31N/A

Clever Leaves' return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Clever LeavesN/A N/A N/A
Vincerx Pharma N/A -248.33%-132.73%

6.9% of Clever Leaves shares are owned by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are owned by institutional investors. 8.2% of Clever Leaves shares are owned by company insiders. Comparatively, 15.6% of Vincerx Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Clever Leaves' average media sentiment score of 0.00 equaled Vincerx Pharma'saverage media sentiment score.

Company Overall Sentiment
Clever Leaves Neutral
Vincerx Pharma Neutral

Summary

Clever Leaves beats Vincerx Pharma on 6 of the 9 factors compared between the two stocks.

How does Vincerx Pharma compare to Scopus BioPharma?

Scopus BioPharma (NASDAQ:SCPS) and Vincerx Pharma (NASDAQ:VINC) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

44.0% of Vincerx Pharma shares are owned by institutional investors. 5.1% of Scopus BioPharma shares are owned by insiders. Comparatively, 15.6% of Vincerx Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Scopus BioPharma's return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Scopus BioPharmaN/A N/A N/A
Vincerx Pharma N/A -248.33%-132.73%

Scopus BioPharma has a beta of -0.19, suggesting that its share price is 119% less volatile than the broader market. Comparatively, Vincerx Pharma has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market.

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Vincerx Pharma'saverage media sentiment score.

Company Overall Sentiment
Scopus BioPharma Neutral
Vincerx Pharma Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scopus BioPharmaN/AN/A-$11.61MN/AN/A
Vincerx PharmaN/AN/A-$40.16M-$5.31N/A

Summary

Scopus BioPharma and Vincerx Pharma tied by winning 3 of the 6 factors compared between the two stocks.

Get Vincerx Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for VINC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VINC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

VINC vs. The Competition

Export
MetricVincerx PharmaPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$66K$11.95B$7.09B$12.99B
Dividend YieldN/A2.70%2.58%10.62%
P/E Ratio0.00783.88269.6825.23
Price / SalesN/A738.99598.84100.59
Price / CashN/A67.4570.5350.75
Price / Book0.0010.5513.246.24
Net Income-$40.16M$2.77B$3.45B$347.70M
7 Day PerformanceN/A-0.15%0.77%0.90%
1 Month PerformanceN/A-0.02%1.45%0.91%
1 Year PerformanceN/A161.12%67.12%20.09%

Vincerx Pharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VINC
Vincerx Pharma
N/A$0.01
flat		N/A-67.5%$66KN/AN/A60
AMPE
Ampio Pharmaceuticals
N/A$0.18
flat		N/AN/A$208KN/AN/A20
CARM
Carisma Therapeutics
0.2603 of 5 stars		$0.00
flat		$1.00
+39,900.0%		-99.2%$105K$10.77M0.0020
PTPI
Petros Pharmaceuticals
N/A$0.00
-3.8%		N/A-88.3%$78K$5.11MN/A20
CLVR
Clever Leaves
N/A$0.01
flat		N/A-50.0%$18K$17.42MN/A560

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:VINC) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
Elon’s S-1 Master Plan Could Rewrite the Rules of AI
A researcher who has advised Goldman Sachs, JPMorgan Chase, BlackRock, and Fidelity flew to Starbase after spo...
Altimetry | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Central banks bought 710 tonnes - this fund pays monthly
Gold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...
Investors Alley | Sponsoredtc pixel